Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation

New England Journal of Medicine

Volumn 376, Issue 6, 2017, Pages 536-547

  Lindsley, R C ^a   Saber, W ^e   Mar, B G ^b   Redd, R ^c   Wang, T ^e   Haagenson, M D ^f   Grauman, P V ^d   Hu, Z H ^e   Spellman, S R ^f   Lee, S J ^e,h   Verneris, M R ^g   Hsu, K ⁱ   Fleischhauer, K ^j   Cutler, C ^a   Antin, J H ^a   Neuberg, D ^c   Ebert, B L ^d  

^a Division of Hematology   (United States)

^b Departments of Pediatric Oncology   (United States)

^c Departments of Biostatistics and Computational Biology   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

^f NATIONAL MARROW DONOR PROGRAM   (United States)

^g UNIVERSITY OF MINNESOTA   (United States)

^h Clinical Research Division   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j UNIVERSITY HOSPITAL ESSEN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; COHORT ANALYSIS; DNMT3A GENE; GATA2 GENE; GENE; GENE MUTATION; GENE SEQUENCE; HUMAN; JAK2 GENE; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PIGA GENE; PPM1D GENE; PROGNOSIS; RELAPSE; SBDS GENE; SEQUENCE ANALYSIS; SF3B1 GENE; SRSF2 GENE; TET2 GENE; TP53 GENE; ADOLESCENT; ALLOTRANSPLANTATION; DNA MUTATIONAL ANALYSIS; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TUMOR SUPPRESSOR GENE; YOUNG ADULT;

JAK2 PROTEIN, HUMAN; JANUS KINASE 2; PPM1D PROTEIN, HUMAN; PROTEIN; PROTEIN PHOSPHATASE 2C; RAS PROTEIN; SBDS PROTEIN, HUMAN;

ADOLESCENT; ADULT; CHILD; DNA MUTATIONAL ANALYSIS; GENES, P53; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; JANUS KINASE 2; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; PROTEIN PHOSPHATASE 2C; PROTEINS; RAS PROTEINS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 85012859983     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1611604     Document Type: Article

References (27)

1. Babushok DV, Bessler M. Genetic predisposition syndromes: When should they be considered in the work-up of MDS? Best Pract Res Clin Haematol 2015; 28: 55-68.
2. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391-405.
3. Bejar R, Stevenson KE, Caughey B, et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol 2014; 32: 2691-8.
4. Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013; 122: 3616-27.
5. Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014; 28: 241-7.
6. Shaffer BC, Ahn KW, Hu Z-H, et al. Scoring system prognostic of outcome in patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome. J Clin Oncol 2016; 34: 1864-71.
7. Della Porta MG, Alessandrino EP, Bacigalupo A, et al. Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. Blood 2014; 123: 2333-42.
8. Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004; 104: 579-85.
9. Della Porta MG, Galli A, Bacigalupo A, et al. Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation. J Clin Oncol 2016 September 6 (Epub ahead of print).
10. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009; 9: 701-13.
11. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011; 364: 2496-506.
12. Yoshizato T, Dumitriu B, Hosokawa K, et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. N Engl J Med 2015; 373: 35-47.
13. Boocock GRB, Morrison JA, Popovic M, et al. Mutations in SBDS are associated with Shwachman-Diamond syndrome. Nat Genet 2003; 33: 97-101.
14. Ostergaard P, Simpson MA, Connell FC, et al. Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nat Genet 2011; 43: 929-31.
15. Myers KC, Bolyard AA, Otto B, et al. Variable clinical presentation of Shwachman- Diamond syndrome: update from the North American Shwachman-Dia-mond Syndrome Registry. J Pediatr 2014; 164: 866-70.
16. Donadieu J, Fenneteau O, Beaupain B, et al. Classification of and risk factors for hematologic complications in a French national cohort of 102 patients with Shwachman-Diamond syndrome. Haematologica 2012; 97: 1312-9.
17. Scott BL, Pasquini MC, Logan B, et al. Results of a phase III randomized, multicenter study of allogeneic stem cell transplantation after high versus reduced intensity conditioning in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901. Blood 2015; 126: LBA-8. abstract.
18. Wong TN, Ramsingh G, Young AL, et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 2015; 518: 552-5.
19. Bally C, Ades L, Renneville A, et al. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. Leuk Res 2014; 38: 751-5.
20. Lindsley RC, Mar BG, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood 2015; 125: 1367-76.
21. Corces-Zimmerman MR, Hong W-J, Weissman IL, Medeiros BC, Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci U S A 2014; 111: 2548-53.
22. Murphy DM, Bejar R, Stevenson K, et al. NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes. Leukemia 2013; 27: 2077-81.
23. Ali AY, Abedini MR, Tsang BK. The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation. Oncogene 2012; 31: 2175-86.
24. Kleiblova P, Shaltiel IA, Benada J, et al. Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint. J Cell Biol 2013; 201: 511-21.
25. Swisher EM, Harrell MI, Norquist BM, et al. Somatic mosaic mutations in PPM1D and TP53 in the blood of women with ovarian carcinoma. JAMA Oncol 2016; 2: 370-2.
26. Xie M, Lu C, Wang J, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 2014; 20: 1472-8.
27. Genovese G, Kahler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014; 371: 2477-87.